Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Savage, K.J.
3000  Ergebnisse:
Personensuche X
?
1

Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome ..:

Briggs, R. ; Savage, K. ; Lappin, K.
Leukemia Research.  128 (2023)  - p. 107190 , 2023
Link: https://doi.org/10.1016/..
 
?
2

PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblas..:

Moskowitz, A. ; Savage, K. ; Feldman, T....
Hematological Oncology.  41 (2023)  S2 - p. 351-353 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome ..:

Mutch, A. ; Lappin, K. ; Savage, K.
Leukemia Research.  128 (2023)  - p. 107191 , 2023
Link: https://doi.org/10.1016/..
 
?
4

Impact of the Dark Zone Signature on Central Nervous System..:

Alduaij, W. ; Jiang, A. ; Collinge, B....
Hematological Oncology.  41 (2023)  S2 - p. 294-296 , 2023
Link: https://doi.org/10.1002/..
 
?
5

THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITE..:

Binkley, M. S. ; Flerlage, J. E ; Borchmann, P....
Hematological Oncology.  41 (2023)  S2 - p. 100-101 , 2023
Link: https://doi.org/10.1002/..
 
?
6

PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DA..:

Torka, P. ; Feldman, T. ; Savage, K....
Hematological Oncology.  41 (2023)  S2 - p. 161-162 , 2023
Link: https://doi.org/10.1002/..
 
?
7

CCTG LY18‐A phase I master protocol of novel combination th..:

Assouline, S. ; Villa, D. ; Hay, A....
Hematological Oncology.  41 (2023)  S2 - p. 589-590 , 2023
Link: https://doi.org/10.1002/..
 
?
8

15. The effect of hoof lesion score on sow survivability ov..:

Savage, K. ; Turpin, D.L. ; Clarke, T..
Animal - science proceedings.  14 (2023)  7 - p. 828-829 , 2023
Link: https://doi.org/10.1016/..
 
?
9

The ECHELON-2 Trial: 5-year results of a randomized, phase ..:

Horwitz, S. ; O'Connor, O.A. ; Pro, B....
Annals of Oncology.  33 (2022)  3 - p. 288-298 , 2022
Link: https://doi.org/10.1016/..
 
?
10

S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN..:

Carlo-Stella, C. ; Ansell, S. ; Zinzani, P. L...
HemaSphere.  6 (2022)  - p. 102-103 , 2022
Link: https://doi.org/10.1097/..
 
?
11

P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTO..:

Bachy, E. ; Savage, K. J. ; Huang, H....
HemaSphere.  6 (2022)  - p. 1124-1125 , 2022
Link: https://doi.org/10.1097/..
 
?
12

S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB..:

Hutchings, M. ; Ansell, S. M. ; Straus, D. J....
HemaSphere.  6 (2022)  - p. 101-102 , 2022
Link: https://doi.org/10.1097/..
 
?
13

Multi‐Decadal Carbon Cycle Measurements Indicate Resistance..:

Hollinger, D. Y. ; Davidson, E. A. ; Fraver, S....
Journal of Geophysical Research: Biogeosciences.  126 (2021)  8 - p. , 2021
Link: https://doi.org/10.1029/..
 
?
14

THE TOPOLOGY OF MYC REARRANGEMENTS IN DOUBLE‐HIT LYMPHOMA I..:

Hilton, L. K. ; Collinge, B. ; Ben‐Neriah, S....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
15

CHARACTERIZATION OF THE GENETIC LANDSCAPE OF HIGH‐GRADE B‐C..:

Collinge, B. J. ; Hilton, L. K ; Wong, J....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
1-15